Nasdaq · Healthcare
NewGenIvf Group Ltd (NIVF)
As-reported financials and recent SEC filings for NewGenIvf Group Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$4.7M
Net income
$9.9M
Net margin
—
Diluted EPS
$3.04
ROE
38.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $4.7M | $5.4M | $5.1M | $5.9M | $4.1M |
| Gross profit | $955,846 | $1.8M | $1.7M | $1.5M | $1.0M |
| Operating income | $-10.7M | $-1.2M | $42,242 | $398,705 | $198,758 |
| Net income | $9.9M | $-524,643 | $130,193 | $458,667 | $-533 |
| Diluted EPS | $3.04 | $-0.16 | $0.04 | $0.04 | $0.00 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
6-K2026-07-06
View on EDGAR →6-K2026-07-01
View on EDGAR →6-K2026-06-22
View on EDGAR →6-K2026-06-18
View on EDGAR →6-K2026-06-16
View on EDGAR →3/A2026-06-16
View on EDGAR →6-K2026-06-11
View on EDGAR →42026-06-08
View on EDGAR →Largest Healthcare peers
Go deeper on NIVF
Search NewGenIvf Group Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.